To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we generated
a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike glycoprotein of …

Hepatitis B virus (HBV) persistence may be due to impaired HBV-specific immune
responses being unable to eliminate efficiently or cure infected hepatocytes. The immune …

SARS‐CoV‐2 infection results in impaired interferon response in patients with severe
COVID‐19. However, how SARS‐CoV‐2 interferes with host immune responses is incompletely …

Disclosures: V. Hehle reported a patent to anti-HBV antibodies and methods of use, pending.
M. Beretta reported a patent to anti-HBV antibodies and methods of use, pending. M. …

COVID‐19 vaccines already in use or in clinical development may have reduced efficacy
against emerging SARS‐CoV‐2 variants. In addition, although the neurotropism of SARS‐CoV‐…

As the coronavirus disease 2019 (COVID-19) pandemic continues and new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern emerge, the adaptive …

We report a lentiviral vector harboring the human β2-microglobulin promoter, with predominant
expression in immune cells and minimal proximal enhancers to improve vector safety. …

Hepatitis C virus (HCV) establishes infection using host lipid metabolism pathways that are
thus considered potential targets for indirect anti-HCV strategies. HCV enters the cell via …

Zika virus, a member of the Flaviviridae family, is primarily transmitted by infected Aedes
species mosquitoes. In 2016, Zika infection emerged as a global health emergency for its …

Lentiviral vectors are among the most effective viral vectors for vaccination. In clear contrast
to the reference adenoviral vectors, lentiviral vectors have a high potential for transducing …